Cargando…

Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C

BACKGROUND AND RATIONALE: Most patients with chronic hepatitis C show virological response to telaprevir-based triple therapy, and achieve an end-of-treatment response (ETR). However, some patients showing ETR develop virological relapse. This study was carried out to evaluate factors associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kondo, C, Atsukawa, M, Tsubota, A, Shimada, N, Abe, H, Aizawa, Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944324/ https://www.ncbi.nlm.nih.gov/pubmed/26732192 http://dx.doi.org/10.4103/0022-3859.173191

Ejemplares similares

Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naïve Genotype 1b Chronic Hepatitis C Patients
por: Abe, Hiroshi, et al.
Publicado: (2014)

Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2013)

Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C
por: Yamagiwa, Satoshi, et al.
Publicado: (2017)

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
por: Pradat, Pierre, et al.
Publicado: (2015)

Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection
por: Bichoupan, Kian, et al.
Publicado: (2017)

Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C
por: Brogan, Anita J., et al.
Publicado: (2014)

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
por: Karino, Y, et al.
Publicado: (2014)

Chronic Hepatitis C Therapy in Liver Cirrhosis Complicated by Telaprevir-Induced DRESS
por: Mousa, Omar Y. S., et al.
Publicado: (2014)

Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy
por: Neukam, Karin, et al.
Publicado: (2015)

Telaprevir-based triple therapy following partial splenic arterial embolization for chronic hepatitis C with thrombocytopenia can reduce carcinogenesis and improve hepatic function reserve
por: ISHIKAWA, TORU, et al.
Publicado: (2015)

Feasibility of Telaprevir-Based Triple Therapy in Liver Transplant Patients with Hepatitis C Virus: SVR 24 Results
por: Werner, Christoph R., et al.
Publicado: (2013)

Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C
por: Kato, Keizo, et al.
Publicado: (2019)

Evaluation of Persistence of Resistant Variants with Ultra-Deep Pyrosequencing in Chronic Hepatitis C Patients Treated with Telaprevir
por: Thomas, Xiomara V., et al.
Publicado: (2012)

Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir
por: Gomes, Lenyta Oliveira, et al.
Publicado: (2018)

Formulary Management of the Protease Inhibitors Boceprevir and Telaprevir for Chronic Hepatitis C Virus
por: Tungol, Alexandra, et al.
Publicado: (2011)

Influencing factors on serum 25-hydroxyvitamin D(3) levels in Japanese chronic hepatitis C patients
por: Atsukawa, Masanori, et al.
Publicado: (2015)

Telaprevir
Publicado: (2012)

Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir
por: D’Ambrosio, Roberta, et al.
Publicado: (2012)

Efficacy and tolerability of telaprevir (TVR)-based triple therapy in HIV/HCV-coinfected patients
por: De Los Santos, Ignacio, et al.
Publicado: (2014)

Telaprevir or boceprevir for hepatitis C treatment: a first survey on pharmacoutilization
por: Capuozzo, Maurizio, et al.
Publicado: (2013)

Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfected patients are comparable with hepatitis C monoinfected patients
por: O’Neil, Conar R, et al.
Publicado: (2015)

Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis
por: Cooper, Curtis L, et al.
Publicado: (2012)

Efficacy and Tolerability of Telaprevir for Chronic Hepatitis Virus C Genotype 1 Infection: A Meta-Analysis
por: Kong, Yuan, et al.
Publicado: (2012)

Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study
por: Atsukawa, Masanori, et al.
Publicado: (2013)

Anti-rods/rings autoantibody seropositivity does not affect response to telaprevir treatment for chronic hepatitis C infection
por: Calise, S. John, et al.
Publicado: (2016)

IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders
por: Calisti, Giorgio, et al.
Publicado: (2015)

Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection
por: Thorlund, Kristian, et al.
Publicado: (2012)

Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir
por: De Meyer, Sandra, et al.
Publicado: (2014)

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
por: Colombo, M, et al.
Publicado: (2014)

Impact of Specialty Pharmacy on Telaprevir-Containing 3-Drug Hepatitis C Regimen Persistence
por: Henderson, Rochelle R., et al.
Publicado: (2014)

Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment
por: Chantry, AS, et al.
Publicado: (2014)

Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C
por: Hayashi, N, et al.
Publicado: (2012)

Telaprevir Experience From Turkey
por: Komur, Suheyla, et al.
Publicado: (2015)

Cutaneous Eruption due to Telaprevir
por: Falcão, Eduardo Mastrangelo Marinho, et al.
Publicado: (2015)

Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks
por: Tamai, Hideyuki, et al.
Publicado: (2014)

No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy
por: Hoffmann, Luísa, et al.
Publicado: (2015)

Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study
por: Mangia, Alessandra, et al.
Publicado: (2017)

Comment to “Telaprevir Experience From Turkey”
por: Akar, Tarik, et al.
Publicado: (2015)

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir
por: Johnson, Mark, et al.
Publicado: (2014)

Response to peginterferon plus ribavirin and subsequent retreatment with telaprevir-based triple therapy in a patient with chronic lymphocytic leukaemia and chronic HCV genotype 1b infection
por: Christensen, Stefan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_645jk0r92dl4ciig3n8dcpovil